News ViiV's Dovato HIV pill approved in EU ViiV’s new daily HIV treatment has been approved in the EU, as the company aims to win over patients with a more convenient treatment approach.
News Dynavax cuts staff and cancer R&D, focuses on vaccine US biotech Dynavax has announced staff cutbacks after deciding to focus on its vaccine business, while winding down its immune-oncology research.
News Gilead faces lawsuit over HIV drug pricing Gilead and other pharma companies stand accused of engaging in a scheme to block cheaper competitors to life-saving HIV drugs from entering the market.
News J&J unveils top pipeline prospects, with main focus on cance... Johnson & Johnson has shone the spotlight on the most promising drugs in its pipeline, saying it plans to file 10 major drugs between now and 2023.
News Gilead to donate HIV drug to US government prophylaxis schem... Gilead has announced it will donate its HIV drug Truvada to a US-government led prophylaxis programme to end the epidemic of the disease.
News ViiV files patient-friendly monthly HIV injection in US ViiV Healthcare has submitted its once-monthly two-drug injected treatment for HIV to the US Food and Drug Administration (FDA).
News Europe is facing a surge in STIs, says ECDC Cases of sexually-transmitted infections (STIs) – particularly gonorrhoea and syphilis – are at record levels across 29 European countries.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
